03 August 2023
03 August 2023
Two lots of Lupin’s Tydemy have been recalled due to a decrease in ascorbic acid levels leading to reduced effectiveness.
Approval has been granted for the Lonsurf and bevacizumab combination based on data from the SUNLIGHT study.
The company’s cretostimogene grenadenorepvec is being analysed as a treatment for a number of types of bladder cancer.
HTIT will invest $60m in the JV while Oramed will make an investment of $10m.
CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.
The funding would be used for research and development, service operation, and capacity expansion.
ABM-1310 is currently in Phase I trials at clinical sites in China and the US.
Biogen's $7.3bn acquisition of Reata gives the company access to the only approved drug for Friedreich's Ataxia.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
